The side effects of GLP-1s
GLP-1 Receptor Agonists: The New Wave in Diabetes Management In the realm of diabetes management, GLP-1 (Glucagon-Like Peptide-1) receptor agonists have emerged as a significant breakthrough, garnering considerable attention among healthcare professionals and patients alike
Medical professionals must be prepared to recognize, prevent, and treat these changes through a combination of evidence-based non-surgical techniques, individualized treatment planning, and collaborative care
Improving clinical trial efficiency: thinking outside the box
This distinction argues for careful long-term monitoring in peptide development programs, rather than suggesting that such risks are categorically greater than those of other modalities
Indeed, the history of anti-obesity medications has been marked by several failures due to serious adverse events, such as suicidality, observed only after their usage had become extensive 221,234 a well-known example being the one that led to the withdrawal of the endocannabinoid inverse agonist, rimonabant 235
